Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers an appointment scheduling system for online appointments, reminders, and referral tracking and management; registration solutions to automate patient self-registration; revenue cycle solutions that provide insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network solutions to deliver clinically relevant content to patients. It deploys its platform in a range of modalities, including Phreesia Mobile, a patients’ mobile device; PhreesiaPads, a self-service intake tablets; Phreesia Dashboard, a web-based dashboard for healthcare services clients; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare services clients, including single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies, as well as government entities and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Market Dominance | Phreesia's platform facilitates over 150 million patient visits annually, representing more than 10% of all patient visits in the United States |
Financial Trajectory | Analysts project revenue growth of 13-15% for FY26, with an adjusted EBITDA range implying approximately 900 basis points of margin expansion |
Evolving Business Model | Explore Phreesia's shift towards increasing revenue per client, potentially leading to slower overall growth but significant margin improvements |
Analyst Perspectives | Price targets range from $23 to $34, with most analysts maintaining positive outlooks despite potential challenges in revenue deceleration |
Metrics to compare | PHR | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipPHRPeersSector | |
---|---|---|---|---|
P/E Ratio | −37.6x | −1.4x | −0.5x | |
PEG Ratio | −0.58 | −0.01 | 0.00 | |
Price/Book | 5.7x | 0.7x | 2.6x | |
Price / LTM Sales | 3.7x | 1.4x | 3.3x | |
Upside (Analyst Target) | 17.3% | 27.0% | 43.5% | |
Fair Value Upside | Unlock | 7.2% | 6.3% | Unlock |